Eurasian J Med. 2008 Aug;40(2):79-82.

Neopterin levels in patients with cerebrovascular disease.

The Eurasian journal of medicine

Hizir Ulvi, Habib Emre, Recep Demir, Recep Aygul, Asuman Varoğlu, Fatih Kara

PMID: 25610033 PMCID: PMC4261687

Abstract

OBJECTIVE: The recovery period in ischemic cerebrovascular disease is sometimes long and complicated. It is thought that a systemic inflammatory response plays an important role in this process. Therefore, promising studies have reported that neopterin and other cytokines serve as indicators of the inflammatory response. The present study investigated the effects of cerebrovascular diseases on plasma neopterin.

MATERIALS AND METHODS: We studied 68 consecutive patients under 65 years of age with cerebrovascular disease; the mean age was 52.08±5.74 years (yrs) (ranging from 39 yrs to 64 yrs; 28 female and 40 male). We also studied 29 randomly selected age-matched healthy subjects (control); the mean age was 49.76±13.11 years (yrs) (ranging from 41 yrs to 62 yrs; 12 female and 17 male). Blood samples for assessing plasma levels of neopterin were usually taken within seven days after admission to the hospital and stored at -20°C until analysis. Serum neopterin levels in all the subjects were measured by Enzyme Immunoassay (EÝA) using the BRAHMS method (Neopterin; Diagnostic GmbH, 16761 Berlin, Germany). Differences between the groups' means were analyzed with the Mann-Whitney U test.

RESULTS: The mean values of neopterin levels in patients (mean neopterin levels in patients, 18.51 ± 11.56 nmol/L; vs. control, 12.26 ± 3.87 nmol/L [p=.001]) were significantly different when compared with the controls.

CONCLUSION: It has been suggested that the mortality and morbidity associated with cerebrovascular disease could be prevented by a reduction in the inflammatory response. We suggest that plasma neopterin levels were significantly increased. So, the levels of plasma neopterin may be useful monitoring of treatment and course of diseases.

Keywords: Ischemic cerebrovascular disease; Neopterin; Systemic inflammatory response

References

1. Stroke. 1999 Feb;30(2):321-7 - PubMed
2. Clin Exp Immunol. 1997 Dec;110(3):492-9 - PubMed
3. Neurology. 1999 Jan 1;52(1):29-33 - PubMed
4. Stroke. 1997 Jun;28(6):1233-44 - PubMed
5. J Neurol Sci. 2001 Nov 15;192(1-2):41-7 - PubMed
6. Stroke. 1998 Oct;29(10 ):2129-35 - PubMed
7. Stroke. 1995 Mar;26(3):373-9 - PubMed
8. J Cereb Blood Flow Metab. 1995 Jul;15(4):547-51 - PubMed
9. BMC Neurol. 2004 Jan 15;4:2 - PubMed
10. FEBS Lett. 1996 Nov 18;397(2-3):263-8 - PubMed
11. Cerebrovasc Dis. 1999;9 Suppl 3:1-8 - PubMed
12. Arch Neurol. 1998 Apr;55(4):481-6 - PubMed
13. Biochim Biophys Acta. 1999 Mar 19;1430(2):387-95 - PubMed
14. Stroke. 1994 Jul;25(7):1481-8 - PubMed
15. Lancet. 1997 Jan 11;349(9045):79-83 - PubMed
16. Biochem Biophys Res Commun. 1998 Jul 20;248(2):341-6 - PubMed
17. Stroke. 1995 Aug;26(8):1393-8 - PubMed
18. J Mol Cell Cardiol. 2000 Jul;32(7):1265-74 - PubMed
19. Stroke. 2000 May;31(5):1062-8 - PubMed
20. Stroke. 2003 Mar;34(3):671-5 - PubMed
21. Ann Neurol. 1995 Jun;37(6):800-5 - PubMed
22. Stroke. 2002 Apr;33(4):982-7 - PubMed
23. Stroke. 2000 Oct;31(10):2325-9 - PubMed
24. Stroke. 1995 Apr;26(4):676-80; discussion 681 - PubMed
25. Neurology. 2001;57(5 Suppl 2):S31-4 - PubMed
26. Immunol Today. 1988 May;9(5):150-5 - PubMed
27. J Cereb Blood Flow Metab. 1999 Sep;19(9):1004-9 - PubMed
28. Crit Rev Clin Lab Sci. 1992;29(3-4):307-41 - PubMed
29. FEBS Lett. 1996 Aug 5;391(1-2):181-4 - PubMed
30. FEBS Lett. 2003 Aug 14;549(1-3):83-6 - PubMed
31. J Neurol Sci. 1999 Jan 15;162(2):185-8 - PubMed
32. Stroke. 1994 Jan;25(1):202-11 - PubMed

Publication Types

• Journal Article